A worldwide scoping review investigating the clinical adoption of value-based healthcare in breast cancer services has found that operational initiatives predominantly concentrate on tracking patient-reported outcomes while leaving financial and payment restructuring largely unaddressed. Published in Frontiers in Oncology, the investigation systematically examined the global peer-reviewed literature published from 2014 to 2026 to determine how healthcare institutions translate conceptual value frameworks into active clinical practice. Value-based healthcare models aim to restructure care delivery by maximizing the health outcomes achieved per unit of cost across the complete cycle of care, a principle especially relevant to breast cancer given its multidisciplinary treatment pathways, extensive survivorship periods, and high global incidence. However, the synthesis of documented programs demonstrates that real-world implementation across hospitals and health networks has generated an asymmetrical care architecture where outcome measurement has matured substantially, but sophisticated economic accounting and bundled reimbursement models remain rare exceptions.
The context surrounding the study reflects an escalating global disease burden alongside rising clinical resource requirements. Global epidemiological estimates recorded approximately 2.3 million newly diagnosed breast cancer cases and 670,000 associated deaths in 2022, ranking the malignancy as the first or second most commonly diagnosed cancer among women in 183 of 185 surveyed countries. Long-term projections indicate that if current demographic and epidemiological trends continue unabated, worldwide incidence will expand by 38 percent to reach 3.2 million annual cases by 2050, while annual mortality is anticipated to rise by 68 percent to 1.1 million deaths. The steepest relative escalations in incidence and mortality are projected to occur in low- and middle-income countries, where healthcare delivery systems already operate under acute capital and staffing constraints. These epidemiological patterns indicate that the majority of nations are not currently positioned to achieve the World Health Organization Global Breast Cancer Initiative target of reducing age-standardized mortality by 2.5 percent annually, underlining why delivering increasing volumes of uncoordinated medical services without evaluating comparative value has become financially and operationally unsustainable.
To rigorously map how clinical providers address these demands, the research team conducted a scoping review strictly adhering to the methodological guidelines established by the Joanna Briggs Institute and the PRISMA-ScR reporting standards for scoping reviews. The investigative team prespecified and registered their systematic review protocol on the Open Science Framework under registration DOI 10.17605/OSF.IO/SCV8Q. The research question was developed using the Population, Concept, and Context framework, specifying female breast cancer patients as the target population, value-based healthcare as the core concept, and hospital settings or affiliated health delivery systems as the clinical context. Systematic literature searches were executed in June 2026 across major biomedical citation databases, specifically PubMed, Embase, and Web of Science, utilizing customized controlled vocabulary terms and Boolean queries covering breast cancer, value-based healthcare, patient-reported outcome measures, and integrated clinical pathways. To maintain international and regional comprehensiveness following peer-review feedback, the authors executed a supplementary search on October 27, 2026, within the Latin American and Caribbean Health Sciences Literature database via the Virtual Health Library.
Eligibility criteria strictly required published reports to describe practical, applied implementations of value-based healthcare strategies within breast cancer care environments, encompassing patient-reported outcome measures, patient-reported experience measures, integrated practice units, specialized value management offices, clinical care redesign, and applied cost analyses. The investigators systematically excluded traditional economic evaluations such as stand-alone cost-effectiveness, cost-utility, or budget impact models, as well as preclinical animal models, studies evaluating isolated chemotherapy, screening, or radiotherapy protocols outside integrated value frameworks, and non-peer-reviewed commentaries. Following initial search execution across PubMed, Embase, and Web of Science, 187 records were identified, leaving 185 unique citations after the removal of two duplicate entries. Title and abstract screening excluded 171 records, after which 14 full-text publications were sought and 13 were successfully retrieved for full-text eligibility appraisal. Three publications were excluded at this stage—comprising two conference abstract compilations and one narrative review—while two additional eligible records were identified and integrated via manual organizational source searching. The subsequent LILACS search yielded 1,441 records but identified zero eligible studies meeting inclusion criteria, resulting in a final study cohort of twelve included publications.
Among the twelve included studies, one foundational publication by Ong and colleagues from 2016 described the international modified Delphi consensus process used to develop the International Consortium for Health Outcomes Measurement standard set rather than an active institutional program. Consequently, this study was retained as a descriptive contextual benchmark, leaving eleven distinct implemented programs spanning from 2014 to 2026 to serve as the analytical denominator for all comparative adherence metrics. The eleven operational initiatives originated entirely from high-income jurisdictions, led by the Netherlands with three studies, followed by Spain with three studies—including two multicountry European investigations—the United States with two studies, Australia with two studies, and Taiwan with one nationwide program. Delivery settings were divided between broad, regional or nationwide health system networks, which accounted for seven initiatives, and individual single-center hospital environments, which represented five. Ten programs functioned within public or non-profit provider frameworks, one operated within a private institutional setting in Australia, and one Dutch study did not specify its provider ownership type. Research activity accelerated markedly near the conclusion of the review window, with half of all included papers appearing from 2024 onward, including five published in 2024 alone.
Data extraction mapped program structures against established organizational frameworks, specifically the strategic value agenda originally conceptualized by Porter and Lee, the expanded ten-component value agenda articulated by Van der Nat, and the six-pillar LEADER transformation framework established by Etges and colleagues. Extraction also utilized the classification taxonomy developed by Zanotto and colleagues to categorize author-reported value effects across five distinct performance domains and classify overarching author value perceptions. Coding reliability between independent extraction reviewers prior to reconciliation consensus meetings demonstrated substantial baseline agreement across 297 assigned binary indicators, matching on 242 individual codes for an overall raw agreement rate of 81.5 percent and a Cohen’s kappa coefficient of 0.60 with a bootstrap 95 percent confidence interval ranging from 0.51 to 0.69. By contrast, initial reviewer concordance for the subjective four-level value perception metric yielded agreement on only three of eleven studies, resulting in an unadjusted kappa of 0.04 and requiring structured consensus reconciliation based strictly on the textual concluding statements formulated by the original study authors.
The evaluation revealed that outcome measurement represents the single most consolidated and consistently adopted component across implemented breast cancer value programs. Seven of the eleven active initiatives, or 64 percent, explicitly structured their outcome tracking protocols around the International Consortium for Health Outcomes Measurement standard set for breast cancer. Furthermore, eight programs, representing 73 percent, integrated additional validated survey instruments, most frequently incorporating the EQ-5D three-level or five-level questionnaires, the Functional Assessment of Cancer Therapy-Breast instrument, or the Distress Thermometer. Specific disease modules from the European Organisation for Research and Treatment of Cancer, notably the QLQ-C30 core questionnaire and the breast-specific QLQ-BR45 or predecessor QLQ-BR23 modules, were implemented by five programs each, while four programs deployed the BREAST-Q 2.0 reconstructive surgery instrument. Two programs collected no standardized patient-reported instruments whatsoever, monitoring institutional quality entirely through clinical, process, and administrative parameters. Process indicators, including diagnostic pathway wait times, reoperation rates for positive margins, and guideline-concordant systemic therapies, were monitored by six programs, whereas structural metrics regarding institutional surgical volume were documented by only three.
Cultural and organizational transformation metrics from the extended value agenda exhibited moderate institutional penetration, though operational follow-through remained partial. An embedded culture of value delivery was documented across eight of eleven programs, representing 73 percent, while learning platforms for clinicians, predominantly functioning as multicenter hospital benchmarking networks and inter-hospital tumor boards, were present in six programs. Integrated practice units designed around multidisciplinary breast care teams were identified in five programs, and geographic reach expansion was coded in six programs, typically reflecting the regional dissemination of standardized outcome collection networks rather than the opening of satellite surgical facilities. However, structured clinical action loops displayed noticeable friction: while five programs established explicit clinical outcome targets and five implemented formal quality improvement actions derived from data, both elements occurred together in only four programs, or 36 percent. Communication domains proved even less developed, with shared clinical decision-making protocols documented in only three programs and formal patient information packages provided by just two.
In sharp contrast to the widespread institutionalization of outcome measurement, economic and financing dimensions exhibited substantial systemic underdevelopment across the twelve years of analyzed literature. Strikingly, not a single implemented program among the eleven evaluated applied time-driven activity-based costing to calculate true per-patient resource utilization. Only two programs analyzed financial costs through the formal perspective of the healthcare payer: a nationwide Taiwanese study analyzing longitudinal five-year per-capita medical claims across the single-payer National Health Insurance Administration, and a private Australian pilot mapping Medicare Benefits Schedule and Pharmaceutical Benefits Scheme price rebates alongside patient out-of-pocket expenses. Three additional European initiatives measured provider-side hospital expenditures or general resource utilization, yet because their accounting failed to measure true bottom-up costs or capture comprehensive payer expenditures, they did not meet formal criteria for value agenda financial components. Bundled payment mechanisms were similarly scarce, appearing in only two operational programs: the long-standing Taiwanese national reimbursement program operating since 2001 with cancer registries initiated in 2004, which tied stage-specific payments to institutional performance bonuses, and the Australian pilot covering twelve months of early-stage breast cancer treatment across two commercial insurers. In the remaining nine initiatives, bundled reimbursement was mentioned merely as a speculative policy aspiration.
Adherence to the six pillars of the LEADER implementation framework mirrored this fundamental structural divide between measurement and financing with remarkable fidelity. Accurate outcomes data and rigorous data measurement processes were documented in ten of eleven programs, or 91 percent each, establishing the highest adherence rates within the entire analytical extraction matrix. Impact evaluation was identified in seven programs, and active leadership paired with care integration was identified in six. Conversely, effective multi-stakeholder agreements and financial risk mitigation mechanisms were present in only three programs, or 27 percent each. The identical triad of initiatives—the Taiwanese single-payer program, the Australian private pilot, and an observational Basque Health Service value equation analysis—accounted for the entirety of positive adherence across both financial LEADER pillars. This empirical alignment indicates that institutional financing and risk-sharing mechanisms behave as an interdependent operational cluster that requires broad health system-level restructuring, remaining largely unattainable for clinical hospital departments attempting value transformation through isolated local effort.
When examining program performance through the outcome classification established by Zanotto and colleagues, reported positive impacts clustered within areas directly tied to measurement routines rather than economic or survival gains. Positive improvements in patient-reported outcome measures, enhanced healthcare provider education and value culture, and improved hospital administrative management were each documented by seven of eleven programs, or 64 percent. By comparison, positive financial outcomes, such as reduced overall expenditure variability or demonstrable cost savings, were reported by five programs, and verifiable clinical outcome improvements, such as lower surgical complication or readmission rates, were reported by four. In terms of overall author value perceptions, four initiatives were classified as positive based on demonstrable institutional improvements directly attributable to program workflows. Six programs were classified as partially positive, reflecting demonstrated implementation feasibility, measurement tool refinement, or favorable preliminary findings that remained insufficient to prove overarching clinical impact. One program did not evaluate impact, and no program reported negative outcomes.
The study authors highlighted several vital contextual and methodological limitations inherent to the global evidence base. The geographic distribution of published literature is severely skewed, with all eleven operational programs situated in high-income economies and complete absence of scientific reports from Latin America, Africa, and South or Southeast Asia. While non-indexed regional initiatives may exist, an exploratory search within Latin American databases using English filters identified zero eligible studies, underscoring an urgent evidence deficit given that low- and middle-income regions face the fastest projected increases in breast cancer mortality. Methodologically, the review adhered to scoping review standards by omitting formal critical appraisal or risk-of-bias grading of primary sources, meaning reported findings reflect self-reported author descriptions rather than verified intervention efficacy. Binary presence-or-absence coding likewise could not capture varying levels of implementation depth or long-term institutional sustainability. Addressing this persistent imbalance will require future implementation initiatives to align standardized patient-reported outcome registries with formalized risk-sharing contracts and bottom-up cost tracking methodologies.
Subject of Research: Scoping review of implemented value-based healthcare programs in breast cancer care
Article Title: Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs
Article References: de Lima, V. C. B. F., Messias, A. C. R., de Melo, R. C., Batista, B. P. D. S. N., Makdissi, F. B. A., Chibana, A. Y., & Etges, A. P. B. D. S. (2026). Mapping value-based healthcare in breast cancer: a scoping review of implemented value programs. Frontiers in Oncology, 16, Article 2031005. https://doi.org/10.3389/fonc.2026.2031005
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.2031005
Keywords: Breast cancer, Value-based healthcare, Scoping review, Patient-reported outcome measures, ICHOM standard set, Time-driven activity-based costing, Bundled payments, LEADER framework, Health outcomes, Integrated practice units, Healthcare financing, Clinical indicators, Quality improvement, Cancer registries, Health systems research, Oncology care delivery
News Source: Nathaniel Bowman. (November 18, 2026). Breast Cancer Value Programs Prioritize Outcome Tracking Over System Payment Reforms. Scienmag.



